Thomas Büchner

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Metzeler Klaus H; Dufour Annika; Benthaus Tobias; Hummel Manuela; Sauerland Maria-Cristina; Heinecke Achim; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Braess Jan; Spiekermann Karsten; Hiddemann Wolfgang; Buske Christian; Bohlander Stefan K
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Braess Jan; Spiekermann Karsten; Staib Peter; Grüneisen Andreas; Wörmann Bernhard; Ludwig Wolf-Dieter; Serve Hubert; Reichle Albrecht; Peceny Rudolf; Oruzio Daniel; Schmid Christoph; Schiel Xaver; Hentrich Marcus; Sauerland Christina; Unterhalt Michael; Fiegl Michael; Kern Wolfgang; Buske Christian; Bohlander Stefan; Heinecke Achim; Baurmann Herrad; Beelen Dietrich W; Berdel Wolfgang E; Büchner Thomas; Hiddemann Wolfgang
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Büchner Thomas; Berdel Wolfgang E; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne; Müller-Tidow Carsten; Braess Jan; Spiekermann Karsten; Kienast Joachim; Staib Peter; Grüneisen Andreas; Kern Wolfgang; Reichle Albrecht; Maschmeyer Georg; Aul Carlo; Lengfelder Eva; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Thomas Büchner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Metzeler Klaus H; Dufour Annika; Benthaus Tobias; Hummel Manuela; Sauerland Maria-Cristina; Heinecke Achim; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Braess Jan; Spiekermann Karsten; Hiddemann Wolfgang; Buske Christian; Bohlander Stefan K
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5031-8.
2009: Braess Jan; Spiekermann Karsten; Staib Peter; Grüneisen Andreas; Wörmann Bernhard; Ludwig Wolf-Dieter; Serve Hubert; Reichle Albrecht; Peceny Rudolf; Oruzio Daniel; Schmid Christoph; Schiel Xaver; Hentrich Marcus; Sauerland Christina; Unterhalt Michael; Fiegl Michael; Kern Wolfgang; Buske Christian; Bohlander Stefan; Heinecke Achim; Baurmann Herrad; Beelen Dietrich W; Berdel Wolfgang E; Büchner Thomas; Hiddemann Wolfgang
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood 2009;113(17):3903-10.
2009: Büchner Thomas; Berdel Wolfgang E; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne; Müller-Tidow Carsten; Braess Jan; Spiekermann Karsten; Kienast Joachim; Staib Peter; Grüneisen Andreas; Kern Wolfgang; Reichle Albrecht; Maschmeyer Georg; Aul Carlo; Lengfelder Eva; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2008: Metzeler Klaus H; Hummel Manuela; Bloomfield Clara D; Spiekermann Karsten; Braess Jan; Sauerland Maria-Cristina; Heinecke Achim; Radmacher Michael; Marcucci Guido; Whitman Susan P; Maharry Kati; Paschka Peter; Larson Richard A; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Hiddemann Wolfgang; Bohlander Stefan K; Buske Christian;
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Blood 2008;112(10):4193-201.
2008: Büchner Thomas; Berdel Wolfgang E; Kienast Joachim
Cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008;359(6):651; author reply 652-3.
2008: Messerer Dorle; Engel Jutta; Hasford Joerg; Schaich Markus; Ehninger Gerhard; Sauerland Cristina; Büchner Thomas; Schumacher Andrea; Krahl Rainer; Niederwieser Dietger; Krauter Jürgen; Ganser Arnold; Creutzig Ursula; Döhner Hartmut; Schlenk Richard F;
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Haematologica 2008;93(6):826-33.
2008: Kessler T; Mohr M; Müller-Tidow C; Krug U; Brunnberg U; Mohr B; Schliemann C; Sauerland C; Serve H; Büchner T; Berdel W E; Mesters R M
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
Leukemia research 2008;32(3):491-4.
2008: Schlenk Richard F; Pasquini Marcelo C; Pérez Waleska S; Zhang Mei-Jie; Krauter Jürgen; Antin Joseph H; Bashey Asad; Bolwell Brian J; Büchner Thomas; Cahn Jean-Yves; Cairo Mitchell S; Copelan Edward A; Cutler Corey S; Döhner Hartmut; Gale Robert Peter; Ilhan Osman; Lazarus Hillard M; Liesveld Jane L; Litzow Mark R; Marks David I; Maziarz Richard T; McCarthy Philip L; Nimer Stephen D; Sierra Jorge; Tallman Martin S; Weisdorf Daniel J; Horowitz Mary M; Ganser Arnold;
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):187-96.
2008: Creutzig Ursula; Büchner Thomas; Sauerland Maria C; Zimmermann Martin; Reinhardt Dirk; Döhner Hartmut; Schlenk Richard F
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Cancer 2008;112(3):562-71.
2007: Schliemann C; Bieker R; Thoennissen N; Gerss J; Liersch R; Kessler T; Büchner T; Berdel W E; Mesters R M
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):1901-6.
2007: Büchner Thomas; Krug Utz; Berdel Wolfgang E; Heinecke Achim; Sauerland Maria Cristina; Wörmann Bernhard; Hiddemann Wolfgang
Maintenance for acute myeloid leukemia revisited.
Current treatment options in oncology 2007;8(4):296-304.
2007: Schaich Markus; Schlenk Richard F; Al-Ali Haifa K; Döhner Hartmut; Ganser Arnold; Heil Gerhard; Illmer Thomas; Krahl Rainer; Krauter Jürgen; Sauerland Cristina; Büchner Thomas; Ehninger Gerhard
Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
Haematologica 2007;92(6):763-70.
2007: Agrawal Shuchi; Unterberg Matthias; Koschmieder Steffen; zur Stadt Udo; Brunnberg Uta; Verbeek Walter; Büchner Thomas; Berdel Wolfgang E; Serve Hubert; Müller-Tidow Carsten
DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Cancer research 2007;67(3):1370-7.
2007: Krug Utz; Serve Hubert; Müller-Tidow Carsten; Mesters Rolf M; Steffen Björn; Büchner Thomas; Berdel Wolfgang E
New molecular therapy targets in acute myeloid leukemia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;176():243-62.
2006: Kulimova Emma; Oelmann Elisabeth; Bisping Guido; Kienast Joachim; Mesters Rolf M; Schwäble Joachim; Hilberg Frank; Roth Gerald J; Munzert Gerd; Stefanic Martin; Steffen Björn; Brandts Christian; Müller-Tidow Carsten; Kolkmeyer Astrid; Büchner Thomas; Serve Hubert; Berdel Wolfgang E
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
Molecular cancer therapeutics 2006;5(12):3105-12.
2006: Saussele S; Adam K; Hochhaus A; Béné M C; Büchner T; Burnett A; Finazzi G; Fonatsch C; Gluckman E; Gökbuget N; Grimwade D J; Haferlach T; Hallek M; Hasford J; Hoelzer D; Ljungman P; Niederwieser D; Serve H; Simonsson B; de Witte T J; Hehlmann R;
[Clinical research at the European LeukemiaNet]
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Büchner Thomas; Berdel Wolfgang E; Schoch Claudia; Haferlach Torsten; Serve Hubert L; Kienast Joachim; Schnittger Susanne; Kern Wolfgang; Tchinda Joelle; Reichle Albrecht; Lengfelder Eva; Staib Peter; Ludwig Wolf-Dieter; Aul Carlo; Eimermacher Hartmut; Balleisen Leopold; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Saussele Susanne; Berger Ute; Aul Carlo; Büchner Thomas; Döhner Hartmut; Ehninger Gerhard; Ganser Arnold; Gökbuget Nicola; Hoelzer Dieter; Uberla Karl; Hehlmann Rüdiger
[Clinical research within the German competence net "acute and chronic leukemias"]
Medizinische Klinik (Munich, Germany : 1983) 2006;101(5):414-20.
2006: Tchinda Joëlle; Volpert Sarah; Berdel Wolfgang E; Büchner Thomas; Horst Jürgen
Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2006;165(2):180-4.
2006: Albrecht Oliver; Serve Hubert; Tchinda Joelle; Zühlsdorf Michael; Büchner Thomas; Bremer Christoph; Parwaresch Reza; Berdel Wolfgang E
Acute myeloid leukemia presenting with a uterus tumor.
Annals of hematology 2006;85(1):58-9.
2005: Büchner Thomas; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Haferlach Torsten; Schnittger Susanne; Kern Wolfgang; Aul Carlo; Lengfelder Eva; Schumacher Andrea; Reichle Albrecht; Staib Peter; Balleisen Leopold; Eimermacher Hartmut; Grüneisen Andreas; Rasche Herbert; Sauerland Maria Cristina; Heinecke Achim; Mesters Rolf M; Serve Hubert L; Kienast Joachim; Hiddemann Wolfgang
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Lengfelder Eva; Saussele Susanne; Weisser Andreas; Büchner Thomas; Hehlmann Rüdiger
Treatment concepts of acute promyelocytic leukemia.
Critical reviews in oncology/hematology 2005;56(2):261-74.
2005: Hiddemann W; Spiekermann K; Buske C; Feuring-Buske M; Braess J; Haferlach T; Schoch C; Kern W; Schnittger S; Berdel W; Wörmann B; Heinecke A; Sauerland C; Büchner Th;
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Berdel Wolfgang E; Kulimova Emma; Kolkmeyer Astrid; Zühlsdorf Michael; Serve Hubert; Büchner Thomas; Oelmann Elisabeth
Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
Annals of hematology 2005;84(12):771-3.
2005: Pavlidis M; Stupp T; Büchner T F; Gerding H
[Acute visual deterioration after "alternative therapy" in Russia]
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2005;102(9):902-5.
2005: Fiegl Michael; Büchner Thomas; Hiddemann Wolfgang; Braess Jan
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Annals of hematology 2005;84(4):227-31.
2004: Hehlmann R; Berger U; Aul C; Büchner Th; Döhner H; Ehninger G; Ganser A; Gökbuget N; Hoelzer D; Uberla K
[The competence network "acute and chronic leukemias"]
Deutsche medizinische Wochenschrift (1946) 2004;129(49):2660-5.
2004: Tchinda Joëlle; Neumann Thomas E; Volpert Sarah; Berdel Wolfgang E; Büchner Thomas; Horst Jürgen
Characterization of chromosomal rearrangements in hematological diseases using spectral karyotyping.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2004;13(3):190-5.
2004: Schlenk R F; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3741-50.
2004: Büchner Thomas; Döhner Hartmut; Ehninger Gerhard; Ganser Arnold; Niederwieser Dietger; Hasford Joerg
Cross-trial networking in AML: a step forward rather than corner cutting.
Leukemia research 2004;28(6):649-50.
2004: Haferlach Torsten; Kern Wolfgang; Schoch Claudia; Schnittger Susanne; Sauerland Maria Cristina; Heinecke Achim; Büchner Thomas; Hiddemann Wolfgang;
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Hehlmann R; Berger U; Aul C; Büchner T; Döhner H; Ehninger G; Ganser A; Hoelzer D; Gökbuget N; Uberla K
[Clinical research in the "acute and chronic leukemias"competence network ]
Der Internist 2004;45(4):384-92.
2004: Müller-Tidow C; Metzelder S K; Buerger H; Packeisen J; Ganser A; Heil G; Kügler K; Adigüzel G; Schwäble J; Steffen B; Ludwig W-D; Heinecke A; Büchner T; Berdel W E; Serve H
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(4):720-6.
2004: Müller-Tidow Carsten; Schwäble Joachim; Steffen Björn; Tidow Nicola; Brandt Burkhardt; Becker Kerstin; Schulze-Bahr Eric; Halfter Hartmut; Vogt Ulf; Metzger Ralf; Schneider Paul M; Büchner Thomas; Brandts Christian; Berdel Wolfgang E; Serve Hubert
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1241-9.
2004: Tchinda J; Volpert S; Liersch R; Zühlsdorf M; Serve H; Neumann T; Kennerknecht I; Berdel W E; Büchner T; Horst J
A cryptic insertion (17;15) on both chromosomes 17 with lack of PML-RARA expression in a case of atypical acute promyelocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):183-6.
2004: Kienast J; Stelljes M; Berning B; Kröger M; Sauerland M C; Heinecke A; Schoch C; Wörmann B; Büchner T; Hiddemann W; Berdel W E;
Transplantation strategies in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S136-7.
2004: Büchner Th; Hiddemann W; Berdel W E; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Balleisen L; Grüneisen A; Aul C; Lengfelder E; Hehlmann R; Kern W; Serve H L; Mesters R M; Eimermacher H; Frickhofen N; Kienast J; Giagounidis A; Sauerland M C; Heinecke A;
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Hiddemann W; Kern W; Heinecke A; Sauerland C; Büchner Th;
Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG.
Annals of hematology 2004;83 Suppl 1():S53-4.
2004: Kern W; Haferlach T; Schoch C; Sauerland M C; Heinecke A; Wörmann B; Berdel W; Büchner Th; Hiddemann W
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2003: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Fonatsch Christa; Löffler Helmut; Haferlach Torsten; Ludwig Wolf-Dieter; Maschmeyer Georg; Staib Peter; Aul Carlo; Gruneisen Andreas; Lengfelder Eva; Frickhofen Norbert; Kern Wolfgang; Serve Hubert L; Mesters Rolf M; Sauerland Maria Cristina; Heinecke Achim;
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Tchinda Joëlle; Volpert Sarah; McNeil Nicole; Neumann Thomas; Kennerknecht Ingo; Ried Thomas; Büchner Thomas; Serve Hubert; Berdel Wolfgang E; Horst Jürgen; Hilgenfeld Eva
Multicolor karyotyping in acute myeloid leukemia.
Leukemia & lymphoma 2003;44(11):1843-53.
2003: Büchner T F; Schnorbus U; Grenzebach U H; Stupp T; Busse H
[Examination of preschool children for refractive errors. First experience using a handheld autorefractor]
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003;100(11):971-8.
2003: Steffen Björn; Serve Hubert; Berdel Wolfgang E; Agrawal Shuchi; Linggi Bryan; Büchner Thomas; Hiebert Scott W; Müller-Tidow Carsten
Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(14):8448-53.
2003: Bieker Ralf; Lerchenmüller Christian; Wehmeyer Jürgen; Serve Hubert L; Mesters Rolf M; Büchner Thomas; Berdel Wolfgang E
Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Oncology reports 2003;10(4):915-20.
2003: Grenzebach Ulrike H; Schnorbus Ulrike; Büchner Thomas; Busse Holger; Stoll Wolfgang
[Development of ocular motility following modified 3-wall decompression of the orbita in endocrine orbitopathy for functional and rehabilitative indication]
Klinische Monatsblätter für Augenheilkunde 2003;220(5):345-51.
2003: Reiter Andreas; Saussele Susanne; Grimwade David; Wiemels Joseph L; Segal Mark R; Lafage-Pochitaloff Marina; Walz Christoph; Weisser Andreas; Hochhaus Andreas; Willer Andreas; Reichert Anja; Büchner Thomas; Lengfelder Eva; Hehlmann Rüdiger; Cross Nicholas C P
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
2003: Haferlach Torsten; Schoch Claudia; Löffler Helmut; Gassmann Winfried; Kern Wolfgang; Schnittger Susanne; Fonatsch Christa; Ludwig Wolf-Dieter; Wuchter Christian; Schlegelberger Brigitte; Staib Peter; Reichle Albrecht; Kubica Uschi; Eimermacher Hartmut; Balleisen Leopold; Grüneisen Andreas; Haase Detlef; Aul Carlo; Karow Jochen; Lengfelder Eva; Wörmann Bernhard; Heinecke Achim; Sauerland Maria Cristina; Büchner Thomas; Hiddemann Wolfgang
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2002: Büchner Thomas; Döhner Hartmut; Ehninger Gerhard; Ganser Arnold; Hasford Jörg;
Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies.
Leukemia research 2002;26(12):1073-5.
2002: Büchner T; Hiddemann W
[Therapeutic strategies in acute myeloid leukemia]
Der Internist 2002;43(10):1203-4, 1207-11.
2002: Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel W E; Mesters R M
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(7):1302-10.
2002: Schnittger Susanne; Schoch Claudia; Dugas Martin; Kern Wolfgang; Staib Peter; Wuchter Christian; Löffler Helmut; Sauerland Cristina Maria; Serve Hubert; Büchner Thomas; Haferlach Torsten; Hiddemann Wolfgang
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Büchner T; Fegeler W; Bernhardt H; Brockmeyer N; Duswald K-H; Herrmann M; Heuser D; Jehn U; Just-Nübling G; Karthaus M; Maschmeyer G; Müller F-M; Müller J; Ritter J; Roos N; Ruhnke M; Schmalreck A; Schwarze R; Schwesinger G; Silling G;
Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2002;21(5):337-52.
2002: Schumacher Andrea; Wewers Dieter; Heinecke Achim; Sauerland Cristina; Koch Olaf M; van de Loo Jürgen; Büchner Thomas; Berdel Wolfgang E
Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia.
Leukemia research 2002;26(4):355-62.
2002: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang; Wörmann Bernhard; Schoch Claudia; Löffler Helmut; Haferlach Torsten; Schumacher Andrea; Staib Peter; Balleisen Leopold; Grüneisen Andreas; Rasche Herbert; Aul Carlo; Heyll Axel; Lengfelder Eva; Ludwig Wolf-Dieter; Maschmeyer Georg; Eimermacher Hartmut; Karow Jochen; Frickhofen Norbert; Hirschmann Wolf-Dietrich; Sauerland Maria-Cristina;
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: Tchinda Joëlle; Volpert Sarah; Neumann Thomas; Kennerknecht Ingo; Ritter Jörg; Büchner Thomas; Berdel Wolfgang E; Horst Jürgen
Novel der(1)t(1;19) in two patients with myeloid neoplasias.
Cancer genetics and cytogenetics 2002;133(1):61-5.
2001: Fonatsch C; Nowotny H; Pittermann-Höcker E; Streubel B; Jäger U; Valent P; Büchner T; Lechner K
Amplification of ribosomal RNA genes in acute myeloid leukemia.
Genes, chromosomes & cancer 2001;32(1):11-7.
2001: Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis H E; Hartlapp J; Hirschmann W D; Weh H J; Pielken H J; Gassmann W; Sauerland M C; Heinecke A
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Mesters R M; Padró T; Bieker R; Steins M; Kreuter M; Göner M; Kelsey S; Scigalla P; Fiedler W; Büchner T; Berdel W E
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Blood 2001;98(1):241-3.
2001: Hilgenfeld E; Padilla-Nash H; McNeil N; Knutsen T; Montagna C; Tchinda J; Horst J; Ludwig W D; Serve H; Büchner T; Berdel W E; Schröck E; Ried T
Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2.
British journal of haematology 2001;113(2):305-17.
2001: Lerchenmüller C; Göner M; Büchner T; Berdel W E
Rhinocerebral zygomycosis in a patient with acute lymphoblastic leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):415-9.
2001: Jahns-Streubel G; Braess J; Schoch C; Fonatsch C; Haase D; Binder C; Wörmann B; Büchner T; Hiddemann W
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(3):377-84.
2001: Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland M C; Heinecke A; Büchner T; Hiddemann W;
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2000: Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel W E; Serve H
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Blood 2000;96(12):3907-14.
2000: Büchner T; Hiddemann W; Wörmann B; Löffler H; Ludwig W D; Schoch C; Haferlach T; Maschmeyer G; Staib P; Aul C; Heyll G A; Grüneisen A; Rasche H; Eimermacher J H; Balleisen L; Pielken H J; Reis H E; Griesinger F; Reichle A; Sauerland M C; Heinecke A;
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Lengfelder E; Reichert A; Schoch C; Haase D; Haferlach T; Löffler H; Staib P; Heyll A; Seifarth W; Saussele S; Fonatsch C; Gassmann W; Ludwig W D; Hochhaus A; Beelen D; Aul C; Sauerland M C; Heinecke A; Hehlmann R; Wörmann B; Hiddemann W; Büchner T
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1362-70.
2000: Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig W D
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Haematologica 2000;85(7):711-21.
2000: Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(5):796-804.
2000: Padró T; Ruiz S; Bieker R; Bürger H; Steins M; Kienast J; Büchner T; Berdel W E; Mesters R M
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Blood 2000;95(8):2637-44.
2000: Streubel B; Valent P; Jäger U; Edelhäuser M; Wandt H; Wagner T; Büchner T; Lechner K; Fonatsch C
Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome.
Genes, chromosomes & cancer 2000;27(4):380-6.
1999: Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig W D
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(12):1943-53.
1999: Hiddemann W; Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T
Management of acute myeloid leukemia in elderly patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3569-76.
1999: Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
[The therapy of acute myeloid leukemia in patients of advanced age]
Deutsche medizinische Wochenschrift (1946) 1999;124(34-35):1005-14.
1999: Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig W D; Sauerland M C; Heinecke A
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1999: Griesinger F; Pirò-Noack M; Kaib N; Falk M; Renziehausen A; Troff C; Grove D; Schnittger S; Büchner T; Ritter J; Hiddemann W; Wörmann B
Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome.
British journal of haematology 1999;105(1):241-55.
1999: Büchner T
[Acute myeloid leukemia (AML)]
Praxis 1999;88(10):421-30.
1999: Gökbuget N; Arnold R; Büchner T; Freund M; Gassmann W; Heil G; Hiddemann W; Löffler H; Lipp T; Ludwig W D; Maschmeyer G; Thiel E; Messerer D; Hoelzer D
[Treatment of adult acute lymphoblastic leukemia]
Praxis 1999;88(10):407-20.
1999: Silling G; Fegeler W; Roos N; Essink M; Büchner T
Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine.
Mycoses 1999;42 Suppl 2():101-4.
1999: Verbeek W; Wörmann B; Koch P; Aul C; Hinrichs H F; Balleisen L; Rowe J M; Bennett J; Haase D; Fonatsch C; Heinecke A; Büchner T; Hiddemann W
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1999;125(6):369-74.
1998: Kratz-Albers K; Zühlsdorp M; Leo R; Berdel W L; Büchner T; Serve H
Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2.
Blood 1998;92(11):4485-7.
1998: Kern W; Braess J; Grote-Metke A; Kuse H; Fuchs R; Hossfeld D K; Reichle A; Wörmann B; Büchner T; Hiddemann W
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1522-6.
1998: Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Annals of hematology 1998;77(3):115-22.
1998: Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Cancer 1998;83(2):291-301.
1998: Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig W D; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(7):1049-55.
1998: Dreyling M H; Schrader K; Fonatsch C; Schlegelberger B; Haase D; Schoch C; Ludwig W; Löffler H; Büchner T; Wörmann B; Hiddemann W; Bohlander S K
MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.
Blood 1998;91(12):4662-7.
1998: Büchner T; Busse H; Gerding H
[Intraocular lens implantation in childhood. Functional results and complications]
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 1998;95(5):307-16.
1998: Schumacher A; Kessler T; Büchner T; Wewers D; van de Loo J
Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(4):586-92.
1998: Streubel B; Sauerland C; Heil G; Freund M; Bartels H; Lengfelder E; Wandt H; Ludwig W D; Nowotny H; Baldus M; Grothaus-Pinke B; Büchner T; Fonatsch C
Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12.
British journal of haematology 1998;100(3):521-33.
1997: Schoch C; Haase D; Fonatsch C; Haferlach T; Löffler H; Schlegelberger B; Hossfeld D K; Becher R; Sauerland M C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Zühlsdorf M; von Eiff M; Thomas M; Büchner T
Decrease in arterial oxygen partial pressure within the first 24 h of rhGM-CSF administration in AML patients.
European journal of haematology 1997;59(5):293-8.
1997: Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Blood 1997;90(5):1968-76.
1997: Verbeek W; Wörmann B; Koch P; Aul C; Hinrichs H; Balleisen L; Rowe J M; Bennett J; Büchner T; Hiddemann W
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Annals of hematology 1997;74(5):205-8.
1997: Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(4):561-71.
1997: Büchner T; Hiddemann W; Wörmann B; Zühlsdorf M; Rottmann R; Innig G; Maschmeier G; Ludwig W D; Sauerland M C; Heinecke A
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
Seminars in oncology 1997;24(1):124-31.
1997: Büchner T
Treatment of adult acute leukemia.
Current opinion in oncology 1997;9(1):18-25.
1997: Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1996: Schumacher A; Kessler T; Riedel A; Büchner T; van de Loo J
[Quality of life and coping with illness in patients with acute myeloid leukemia]
Psychotherapie, Psychosomatik, medizinische Psychologie 1996;46(11):385-90.
1996: Haferlach T; Bennett J M; Löffler H; Gassmann W; Andersen J W; Tuzuner N; Casslleth P A; Fonatsch C; Schoch C; Schlegelberger B; Becher R; Thiel E; Ludwig W D; Sauerland M C; Heinecke A; Büchner T
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Leukemia & lymphoma 1996;23(3-4):227-34.
1996: Hoelzer D; Gökbuget N; Arnold R; Büchner T; Freund M; Gassmann W; Heil G; Hiddemann W; Löffler H; Lipp T; Ludwig W D; Maschmeyer G; Thiel E; Messerer D
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy]
Der Internist 1996;37(10):994-1007.
1996: Schoch C; Haase D; Haferlach T; Freund M; Link H; Lengfelder E; Löffler H; Büchner T; Fonatsch C
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.
British journal of haematology 1996;94(3):493-500.
1996: Müller C; Kremerskothen J; Zühlsdorf M; Cassens U; Büchner T; Barnekow A; Koch O M
Rapid quantitative analysis of protein tyrosine residue phosphorylation in defined cell populations in whole blood and bone marrow aspirates.
British journal of haematology 1996;94(3):461-3.
1996: Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland M C; Löffler H; Fonatsch C
Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(8):1288-95.
1996: Gahn B; Haase D; Unterhalt M; Drescher M; Schoch C; Fonatsch C; Terstappen L W; Hiddemann W; Büchner T; Bennett J M; Wörmann B
De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):946-51.
1996: Büchner T; Heinecke A
The role of prognostic factors in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 1():S28-9.
1996: Hoelzer D; Ludwig W D; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel T H; Gramatzki M; Diedrich H; Kolbe K; Fuhr H G; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Blood 1996;87(2):495-508.
1995: Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1857-63.
1995: Sperling C; Büchner T; Creutzig U; Ritter J; Harbott J; Fonatsch C; Sauerland C; Mielcarek M; Maschmeyer G; Löffler H
Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML.
Leukemia & lymphoma 1995;17(5-6):417-26.
1995: von Eiff M; Zühlsdorf M; Roos N; Thomas M; Büchner T; van de Loo J
Pulmonary infiltrates in patients with haematologic malignancies: clinical usefulness of non-invasive bronchoscopic procedures.
European journal of haematology 1995;54(3):157-62.
1994: Wörmann B; Reuter C; Zühlsdorf M; Büchner T; Hiddemann W
Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
Seminars in oncology 1994;21(6 Suppl 16):39-43.
1994: Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Seminars in oncology 1994;21(6 Suppl 16):33-8.
1994: Büchner T
Hematopoietic growth factors in cancer treatment.
Stem cells (Dayton, Ohio) 1994;12(3):241-52.
1994: Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(2):217-25.
1994: Büchner T
The role of hematopoietic growth factors in the treatment of cancer and leukemias.
Acta haematologica Polonica 1994;25(2 Suppl 1):71-83.
1993: Sperling C; Büchner T; Sauerland C; Fonatsch C; Thiel E; Ludwig W D
CD34 expression in de novo acute myeloid leukaemia.
British journal of haematology 1993;85(3):635-7.
1993: Hoelzer D; Thiel E; Ludwig W D; Löffler H; Büchner T; Freund M; Heil G; Hiddemann W; Maschmeyer G; Völkers B
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7 Suppl 2():S130-4.
1993: Kusnierz-Glaz C R; Normann D; Weinberg R; Fuchs R; Flasshove M; Hiddemann W; van de Loo J; Büchner T
Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia.
Hematological oncology 1993;11(2):73-80.
1993: Sperling C; Seibt-Jung H; Gassmann W; Komischke B; Sauerland C; Hiddemann W; Löffler H; Büchner T; Thiel E; Ludwig W D
Immunophenotype of acute myeloid leukemia: correlation with morphological characteristics and therapy response.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():381-92.
1993: Wörmann B; Safford M; Könemann S; Büchner T; Hiddemann W; Terstappen L W
Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():185-96.
1993: Büchner T; Hiddemann W; Wörmann B; Rottmann R; Maschmeyer G; Ludwig W D; Zühlsdorf M; Buntkirchen K; Sander A; Aswald J
The role of GM-CSF in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():21-4.
1992: Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(12):1273-80.
1992: Büchner T; Hiddemann W; Schaefer U W; Löffler H; Maschmeyer G; Ludwig W D; Aul C; Lathan B; Heinecke A
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 4():68-70.
1992: Terstappen L W; Safford M; Unterhalt M; Könemann S; Zurlutter K; Piechotka K; Drescher M; Aul C; Büchner T; Hiddemann W
Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(10):993-1000.
1992: Büchner T; Roos N
Antifungal treatment strategy in leukemia patients.
Annals of hematology 1992;65(4):153-61.
1992: Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Seminars in oncology 1992;19(2 Suppl 4):31-7.
1992: Terstappen L W; Safford M; Könemann S; Loken M R; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(1):70-80.
1992: Büchner T; Hiddemann W; Wörmann B; Löffler H; Maschmeyer G; Hossfeld D; Ludwig W D; Nowrousian M; Aul C; Schaefer U W
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():68-71.
1992: Hoelzer D; Thiel E; Ludwig W D; Löffler H; Büchner T; Freund M; Heil G; Hiddemann W; Maschmeyer G; Völkers B
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():175-7.
1991: Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire E A; Innig G; Maschmeyer G; Ludwig W D
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood 1991;78(5):1190-7.
1991: Hiddemann W; Essink M E; Fegeler W; Zühlsdorf M; Sauerland C; Büchner T
Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia.
Cancer 1991;68(1):9-14.
1991: Horowitz M M; Messerer D; Hoelzer D; Gale R P; Neiss A; Atkinson K; Barrett A J; Büchner T; Freund M; Heil G
Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.
Annals of internal medicine 1991;115(1):13-8.
1991: Büchner T; Hiddemann W; Löffler G; Gassmann W; Maschmeyer G; Heit W; Hossfeld D; Weh H; Ludwig W D; Thiel E
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Seminars in hematology 1991;28(3 Suppl 4):76-9.
1991: Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Annals of hematology 1991;63(1):1-4.
1991: Terstappen L W; Könemann S; Safford M; Loken M R; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(4):315-21.
1991: Koenigsmann M; Hiddemann W; Büchner T
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML.
Leukemia research 1991;15(1):37-41.
1990: Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho A D; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(9):637-40.
1990: Hiddemann W; Schleyer E; Uhrmeister C; Aul C H; Maschmeyer G; Heinecke A; Büchner T
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Cancer treatment reviews 1990;17(2-3):279-85.
1990: von Eiff M; Essink M; Roos N; Hiddemann W; Büchner T; van de Loo J
Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.
Blut 1990;60(4):242-8.
1990: Hiddemann W; Martin W R; Sauerland C M; Heinecke A; Büchner T
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(3):184-8.
1990: Hiddemann W; Büchner T
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Blut 1990;60(3):163-71.
1990: Essink M E; Hiddemann W; von Eiff M; Büchner T; van de Loo J
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Haematology and blood transfusion 1990;33():558-9.
1990: von Eiff M; Essink M; Roos N; Schmidt H; Hiddemann W; Büchner T; van de Loo J
Hepatosplenic candidiasis in acute leukemias.
Haematology and blood transfusion 1990;33():555-7.
1990: Kusnierz-Glaz C; Reiser M; Hagemeister B; Büchner T; Hiddemann W; van de Loo J
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
Haematology and blood transfusion 1990;33():351-6.
1990: Krehmeier C; Zühlsdorf M; Büchner T; Hiddemann W
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
Haematology and blood transfusion 1990;33():129-32.
1990: Hiddemann W; Zühlsdorf M; Wörmann B; Koenigsmann M; Büchner T
Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
Leukemia research 1990;14(4):347-52.
1990: Büchner T; Hiddemann W; Koenigsmann M; Zuehlsdorf M; Woermann B; Boeckmann A; Aguion Freire E; Innig G; Maschmeyer G; Ludwig W D
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse.
Haematology and blood transfusion 1990;33():724-31.
1990: Ludwig W D; Thiel E; Bartram C R; Kranz B R; Raghavachar A; Löffler H; Ganser A; Büchner T; Hiddemann W; Heil G
Clinical importance of T-ALL subclassification according to thymic or prethymic maturation stage.
Haematology and blood transfusion 1990;33():419-27.
1990: Heinecke A; Sauerland M C; Büchner T
Sequential decision strategy of the AML Cooperative Group studies.
Haematology and blood transfusion 1990;33():290-4.
1990: Heinecke A; Sauerland M C; Büchner T
Predictive models for achievement of complete remission and duration of first remission in adult acute myeloid leukemia.
Haematology and blood transfusion 1990;33():285-9.
1990: Büchner T; Hiddemann W; Blasius S; Koch P; Maschmeyer G; Tirier C; Sodomann H; Kuse R; Thiel E; Ludwig W D
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Haematology and blood transfusion 1990;33():261-6.
1990: Büchner T; Hiddemann W; Maschmeyer G; Ludwig W; Löffler H; Nowrousian M; Aul C; Heinecke A
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):97-9.
1990: Hiddemann W; Wörmann B; Messerer D; Springefeld R; Büchner T
Analysis of the cellular DNA and RNA content in acute leukemias by flow cytometry.
Journal of cancer research and clinical oncology 1990;116(5):507-12.
1989: Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hematological oncology 1989;7(4):267-73.
1989: Thiel E; Kranz B R; Raghavachar A; Bartram C R; Löffler H; Messerer D; Ganser A; Ludwig W D; Büchner T; Hoelzer D
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia.
Blood 1989;73(5):1247-58.
1989: Siegert W; Hiddemann W; Koppensteiner R; Büchner T; Essink M; Huhn D; Jung M; Marosi L; Martin T; Minar E
Accidental overdose of mitoxantrone in three patients.
Medical oncology and tumor pharmacotherapy 1989;6(4):275-8.
1988: Büchner T; Hiddemann W; Zühlsdorf M; Koenigsmann M; Böckmann A; van de Loo J; Schulz G
Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk of early death.
Behring Institute Mitteilungen 1988;(83):309-12.
1988: von Eiff M; Essink M; Fegeler W; Schellong S; Schmidt H; Hiddemann W; Büchner T; van de Loo J
[Clinical course and risk factors in patients with generalized mycoses]
Schweizerische medizinische Wochenschrift 1988;118(16):584-91.
1988: Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Kurrle E; Heimpel H; Koch P; Lipp T
[Intensive combined therapy for high-risk ALL patients]
Onkologie 1988;11(1):18-24.
1988: Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Onkologie 1988;11(1):10-2.
1988: Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Koch P; Freund M; Diedrich H; Rühl H
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.
Blood 1988;71(1):123-31.
1987: Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Kurrle E; Heimpel H; Koch P; Lipp T
Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):92-7.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):73-7.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Blood 1987;69(3):744-9.
1987: Büchner T; Urbanitz D; Hiddemann W; Koch P; Pielken H J; Kuse R; Mohr A; Maschmeyer G; Kreutzmann H; Wendt F
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies]
Onkologie 1987;10(1):14-6.
1987: Hiddemann W; Kreutzmann H; Donhuijsen-Ant R; Planker M; Wendt F C; Büchner T
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Onkologie 1987;10(1):11-2.
1987: Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig W D; Maschmeier G; Heinecke A; van de Loo J
Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Haematology and blood transfusion 1987;30():64-8.
1987: Büchner T; Hiddemann W; Urbanitz D; Kreutzmann H; Maschmeyer G; Wendt F; Kuse R; Mohr A; Gassmann W; Löffler H
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Haematology and blood transfusion 1987;30():57-63.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Fuhr H J; Donhuijsen-Ant R; Lengfelder E; Büchner T
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
Haematology and blood transfusion 1987;30():336-8.
1987: Löffler H; Kayser W; Schmitz N; Thiel E; Hoelzer D; Büchner T; Urbanitz D; Spiegel K; Messerer D; Heinecke A
Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany.
Haematology and blood transfusion 1987;30():21-7.
1986: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Onkologie 1986;9(3):144-6.
1986: Büchner T; Urbanitz D; Hiddemann W; Koch P; Pielken H J; Kuse R; Mohr A; Maschmeyer G; Kreutzmann H; Wendt F
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies]
Onkologie 1986;9(2):83-91.
1985: Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig W D; Fischer J; Aul H C; Vaupel H A; Kuse R; Zeile G
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(12):1583-9.
1985: Hiddemann W; Kreutzmann H; Ludwig W D; Aul H C; Donhuijsen-Ant R; Lengfelder E; Büchner T
Mitozantrone and high-dose cytarabine in refractory adult acute myeloid leukaemia.
Lancet 1985;2(8453):508-9.
1985: Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Büchner T
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia]
Onkologie 1985;8(3):181-4.
1985: Urbanitz D; Pielken H J; Koch P; Büchner T; Hiddemann W; Heinecke A; Wendt F; Maschmeier G; van de Loo J
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Onkologie 1985;8(3):157-9.
1985: Büchner T; Urbanitz D; Rühl H; Fischer J; Kuse R
Role of chemotherapy for AML in remission.
Lancet 1985;1(8439):1224-5.
1985: Hoelzer D; Thiel E; Löffler H; Bodenstein H; Büchner T; Engelhardt R; Ganser A; Messerer D; Rühl H; Zwingers T
Risk groups in a multicenter pilot study for treatment of acute lymphoblastic and acute undifferentiated leukemia in adults.
Haematology and blood transfusion 1985;29():48-50.
1984: Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study]
Onkologie 1984;7(4):214-6.
1984: Büchner T; Urbanitz D; Emmerich B; Fischer J; Heinecke A; Hiddemann W; Pfreundschuh M; Rühl H; Wendt F
Long-term remission in acute myelogenous leukaemia.
Lancet 1984;1(8376):571.
1983: Hoelzer D; Thiel E; Löffler H; Bodenstein H; Büchner T; Messerer D
Multicentre pilot study for therapy of acute lymphoblastic and acute undifferentiated leukemia in adults.
Haematology and blood transfusion 1983;28():36-40.
1982: Büchner T; Urbanitz D; Emmerich B; Fischer J T; Fülle H H; Heinecke A; Hossfeld D K; Koeppen K M; Labedzki L; Löffler H; Nowrousian M R; Pfreundschuh M; Pralle H; Rühl H; Wendt F C
Multicentre study on intensified remission induction therapy for acute myeloid leukemia.
Leukemia research 1982;6(6):827-31.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Thomas Büchner

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Thomas Büchner (preview)

All Publications